A7.14 IRF5 Polymorphisms in Systemic Sclerosis
Carmel Stock(Guy's and St Thomas' NHS Foundation Trust), EA Renzoni(Royal Brompton Hospital), CP Denton(The Royal Free Hospital), Carmen Fonseca(The Royal Free Hospital), DJ Abraham(The Royal Free Hospital), Gisela Lindahl(Royal Brompton Hospital), AU Wells(Royal Brompton Hospital), Hajime Satō(National Institute of Public Health)
Cited by 1
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Activation of Fibroblast Procollagen α1(I) Transcription by Mechanical Strain Is Transforming Growth Factor-β-dependent and Involves Increased Binding of CCAAT-binding Factor (CBF/NF-Y) at the Proximal Promoter
|Journal of Biological Chemistry|2002|148
Subclinical neurophysiological effects of lead: A review on peripheral, central, and autonomic nervous system effects in lead workers
|American Journal of Industrial Medicine|2000|142
Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate
|European Neurology|2008|99